More anti-CD40 Agents: Toralizumab and BG9588

I’ve found two more anti-CD40 agents. These have been tested in lupus nephritis (and other diseases). One is called toralizumab and the other is BG9588; I’ve seen riplizumab as a name, which would be bad as RIP means rest in peace. The other name was ruplizumab. Both target CD40 ligand. As there has been a safety signal for thromboembolism, all studies of both MABs have been stopped.

So I guess, we won't see anything on these two MABs concerning SLE or Rheumatoid arthritis.

Links:

https://en.wikipedia.org/wiki/Toralizumab

https://books.google.de/books?id=GMr1VYauOt0C&pg=PA15&lpg=PA15&dq=bg9588&source=bl&ots=vcWaHINH6n&sig=3KefHYSoaTCdYi3psjiqGIvHx3g&hl=de&sa=X&ved=0ahUKEwinttjZudzQAhWJhywKHWkcA70Q6AEIUTAL#v=onepage&q=bg9588&f=false

https://books.google.de/books?id=6CjQyPD2hxEC&pg=PA120&lpg=PA120&dq=riplizumab+Michael+H.+Weisman&source=bl&ots=2DFvffBz0d&sig=_rFMIpuAFHTMv26QgBdLuyUYsWg&hl=de&sa=X&ved=0ahUKEwjZ36KWvNzQAhUCESwKHR74ARAQ6AEINDAD#v=onepage&q=riplizumab%20Michael%20H.%20Weisman&f=false